AI Science Tracker

Institut Pasteur de Tunis

2 discoveries from 2024 to 2026

Discoveries

Tranylcypromine shows in-vitro activity against Leishmania major

The study experimentally tested the previously model-predicted drug tranylcypromine against L. major promastigotes and intracellular amastigotes. It reports IC50 values of 83.6 and 31.6 µg/mL, respectively, and macrophage CC50 of 282.3 µg/mL. These relatively high in-vitro concentrations do not establish achievable exposure, patient safety or clinical efficacy; human monoamine oxidase mechanism is not shown as the parasite target.

Technology: Prior machine-learning drug-repurposing pipeline (the present study is experimental validation)

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Primary full text reports promastigote and intracellular amastigote assays with dose responses and host-cell cytotoxicity.
  • Still unknown: Prior drug/species work, tolerability and mechanism remain unresolved; no clinical inference.
  • AI role: Study experimentally validates a model-prioritized repurposing candidate from earlier research.

Evidence sources: https://doi.org/10.3389/fmicb.2025.1756231

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 16 Nov 2026. Review scope: publisher primary full text; PubMed primary metadata/abstract. Material checked for the specific claims stated in the record..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Machine-learning-predicted approved drugs show in-vitro Leishmania activity

Two classifiers previously prioritized approved drugs from a screened set; ten candidates were purchased for assays against L. major and L. infantum. Five showed dose-dependent effects; intracellular testing and macrophage cytotoxicity were also reported. Domperidone and dibucaine had prior antiparasitic evidence, so the bounded result concerns the study’s remaining tested drugs and assays, not ten novel therapies.

Technology: Random forest and support-vector machine classifiers

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: Primary full text describes ten tested predicted candidates, three Leishmania strains, intracellular testing and host-cell counter-assays.
  • Still unknown: Earlier drug-specific literature, concentrations, achievable exposure and clinical efficacy require separate assessment.
  • AI role: Previously trained activity models selected FDA-approved drugs for experimental parasite and host-cell testing.

Evidence sources: https://doi.org/10.3389/fcimb.2024.1403589

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.

Review date: 16 Nov 2026. Review scope: publisher primary full text. Material checked for the specific claims stated in the record..

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships

No follow-up recorded; this is not a claim that no follow-up exists.

Follow-up review scope and date are not recorded.

No source-supported relationships recorded.

Open the interactive profile for the timeline, or browse all organizations and model families.